BioCentury | Jan 11, 2021
Politics, Policy & Law

Truth and facts matter. Say it out loud: Editor’s Commentary

...results. On Sunday, the Blue Cross Blue Shield...
BioCentury | Dec 5, 2020
Finance

Seer posts triple-digit gain as trio of new listings adds to 2020’s record NASDAQ haul

Three more biotechs gained value in the aftermarket Friday after pricing upsized IPOs, with proteomics company Seer scoring a triple-digit gain while Silverback and Sigilon each rose by double digits. With the trio’s listings, more...
BioCentury | Nov 25, 2020
Regulation

With Oxlumo’s approval, Alnylam aims to speed access with new value-based pricing framework

...Health Care Inc., and Blue Cross Blue Shield’s...
BioCentury | Nov 17, 2020
Politics, Policy & Law

Biden appoints former pharma lobbyist Ricchetti as White House counselor

...Inc. (NYSE:PFE) and the American Hospital Association. Ricchetti headed congressional lobbying for Blue Cross Blue Shield...
...previous years. Steve Usdin Eli Lilly and Co. Pfizer Inc. Genomics Institute of the Novartis Research Foundation Blue Cross Blue Shield Eisai...
BioCentury | Oct 17, 2020
Politics, Policy & Law

Getting FDA back on track

Regardless of the outcome of the elections, FDA is likely to have a new commissioner next year, one who will step into a leadership vacuum that is exhausting the agency’s supply of credibility and...
BioCentury | Oct 8, 2020
Product Development

Trump’s statements sure to increase demand for COVID-19 mAbs

Just hours after Eli Lilly became the first COVID-19 mAb developer to disclose it had requested emergency use authorization, President Donald Trump released a video calling for immediate authorization of both Lilly’s and Regeneron’s mAbs,...
BioCentury | Oct 1, 2020
Politics, Policy & Law

Offit, McClellan testimonies aim to bolster trust in COVID-19 vaccine developers, review process

During a House Committee on Energy and Commerce hearing on Wednesday, Paul Offit and Mark McClellan both highlighted multiple “guardrails” designed to protect the COVID-19 vaccine authorization and approval process from political pressure. Committee members’...
BioCentury | Sep 4, 2020
Regulation

A glimpse at FDA’s vaccine panel ahead of October’s COVID-19 meeting

As FDA’s October advisory committee meeting on COVID-19 vaccines approaches, at least three standing members have signaled publicly that authorization and distribution of a vaccine should not be rushed without scientific evidence.  A roster of the...
BioCentury | Sep 1, 2020
Product Development

Disease setting shields Vir, GSK trial of COVID-19 mAb from plasma EUA

The outpatient setting of the first clinical trial of Vir and GSK’s lead antiviral COVID-19 mAb buffers the study from being affected by FDA’s emergency use authorization for convalescent plasma. The partners also differentiated their...
BioCentury | Jun 27, 2020
Deals

Why the WuXi NextCode split makes strategic sense for the multinational genomics company

...the company is not accessible to shareholders. The hope is that those governance structures will shield...
Items per page:
1 - 10 of 520
BioCentury | Jan 11, 2021
Politics, Policy & Law

Truth and facts matter. Say it out loud: Editor’s Commentary

...results. On Sunday, the Blue Cross Blue Shield...
BioCentury | Dec 5, 2020
Finance

Seer posts triple-digit gain as trio of new listings adds to 2020’s record NASDAQ haul

Three more biotechs gained value in the aftermarket Friday after pricing upsized IPOs, with proteomics company Seer scoring a triple-digit gain while Silverback and Sigilon each rose by double digits. With the trio’s listings, more...
BioCentury | Nov 25, 2020
Regulation

With Oxlumo’s approval, Alnylam aims to speed access with new value-based pricing framework

...Health Care Inc., and Blue Cross Blue Shield’s...
BioCentury | Nov 17, 2020
Politics, Policy & Law

Biden appoints former pharma lobbyist Ricchetti as White House counselor

...Inc. (NYSE:PFE) and the American Hospital Association. Ricchetti headed congressional lobbying for Blue Cross Blue Shield...
...previous years. Steve Usdin Eli Lilly and Co. Pfizer Inc. Genomics Institute of the Novartis Research Foundation Blue Cross Blue Shield Eisai...
BioCentury | Oct 17, 2020
Politics, Policy & Law

Getting FDA back on track

Regardless of the outcome of the elections, FDA is likely to have a new commissioner next year, one who will step into a leadership vacuum that is exhausting the agency’s supply of credibility and...
BioCentury | Oct 8, 2020
Product Development

Trump’s statements sure to increase demand for COVID-19 mAbs

Just hours after Eli Lilly became the first COVID-19 mAb developer to disclose it had requested emergency use authorization, President Donald Trump released a video calling for immediate authorization of both Lilly’s and Regeneron’s mAbs,...
BioCentury | Oct 1, 2020
Politics, Policy & Law

Offit, McClellan testimonies aim to bolster trust in COVID-19 vaccine developers, review process

During a House Committee on Energy and Commerce hearing on Wednesday, Paul Offit and Mark McClellan both highlighted multiple “guardrails” designed to protect the COVID-19 vaccine authorization and approval process from political pressure. Committee members’...
BioCentury | Sep 4, 2020
Regulation

A glimpse at FDA’s vaccine panel ahead of October’s COVID-19 meeting

As FDA’s October advisory committee meeting on COVID-19 vaccines approaches, at least three standing members have signaled publicly that authorization and distribution of a vaccine should not be rushed without scientific evidence.  A roster of the...
BioCentury | Sep 1, 2020
Product Development

Disease setting shields Vir, GSK trial of COVID-19 mAb from plasma EUA

The outpatient setting of the first clinical trial of Vir and GSK’s lead antiviral COVID-19 mAb buffers the study from being affected by FDA’s emergency use authorization for convalescent plasma. The partners also differentiated their...
BioCentury | Jun 27, 2020
Deals

Why the WuXi NextCode split makes strategic sense for the multinational genomics company

...the company is not accessible to shareholders. The hope is that those governance structures will shield...
Items per page:
1 - 10 of 520